

Advance Contract Award Notice (ACAN)
Solicitation Number: 190138

TITLE: *Pharma Intelligence Center – Drugs Database*

1. The purpose and explanation of an ACAN

An Advance Contract Award Notice (ACAN) allows the Patented Medicine Prices Review Board (PMPRB) contracting authorities to post a notice, for no less than fifteen (15) calendar days, indicating to the supplier community that a good, service or construction contract will be awarded to a pre-identified contractor. If no other supplier submits, on or before the closing date, a Statement of Capabilities that meets the requirements set out in the ACAN, the contracting authority may then proceed with the award. However, should a Statement of Capabilities be found to meet the requirements set out in the ACAN, then the contracting authority will proceed to a full tendering process.

2. Rights of suppliers

Suppliers who consider themselves fully qualified and available to provide the services or goods described in this ACAN may submit a Statement of Capabilities demonstrating how they meet the advertised requirement. This Statement of Capabilities must be provided **via e-mail only** to the contact person identified in Section 11 of the Notice, on or before the closing date and time of the Notice. If there is a reasonable level of evidence regarding capability the requirement will be opened to electronic or traditional bidding processes.

3. Proposed Contractor

GlobalData
John Carpenter House
7 Carmelite Street
London EC4Y 0BS, England

4. Definition of Requirements or Expected Results

The PMPRB gathers intelligence on pharmaceutical trends, innovation and Research & Development to carry out its reporting mandate and develop strategic advice for interested parties. To perform these functions, the PMPRB requires considerable resources both internally and externally to gather and analyze the best available information on global pharmaceutical research and development.

5. Minimum requirements

Any interested supplier must demonstrate by way of a Statement of Capabilities that it meets the following minimum requirements:

- An ability to provide comprehensive sources and timely analysis of pharmaceutical trends, innovation and developments in key world markets: (Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, UK and USA). Including news updates by a team of international pharmaceutical experts, fully sourced and linked to primary and secondary information sources, and personal contacts and support.
- Thought Leadership articles and news feeds, providing unique perspectives and insights into horizon scanning, international pharmaceutical trends and R&D topics.
- Consistent methodology to aid in international comparisons; enhanced by the availability of tabular reports to assist in horizon scanning activities and advanced search tools to enable rigorous database interrogation.

6. Reason for non-competitive award

In accordance with the Government Contracts Regulations (GCR) of the *Financial Administration Act*, the following request falls under exception 6(d) of the GCR, which stipulates that only one person or contractor is capable of performing the contract.

GlobalData is a well recognized biopharmaceutical company that provides global pharmaceutical information that is often referenced by key national and international stakeholders. GlobalData has a proven track record with the PMPRB for excellence, timeliness and precision. The subscription will add qualitative and quantitative information to existing databases with the same specifications that would allow for consistent interpretation of findings.

The company has demonstrated expertise in both the collection and interpretation of market data and consistently provided the required information in a complete, objective and non-biased fashion, with supporting documentation. The company uses a wide array of international and external experts to produce well sourced research materials covering innovation and developments in key world markets. Increasingly, the PMPRB has been relying on GlobalData's drug database and clinical trial database for both policy research and reporting purposes such as horizon scanning and international market intelligence. GlobalData provides various domestic and international market insights with substantiating analytics from a network of data suppliers and international experts, which uses a consistent methodology to aid in PMPRB's international comparisons. Additionally, the company provides advanced statistical information that compliments the data and price information housed at the PMPRB, which offers even greater interpretive power to position the PMPRB for future priorities. No other data/market intelligence supplier can provide the type of information that would be sufficient to the needs of the PMPRB.

7. Ownership of Intellectual Property

Ownership of any Foreground Intellectual Property arising out of the proposed contract will vest with the Contractor.

8. Period of the proposed contract

The proposed contract is for a period of one (1) year after the award of the contract with an irrevocable renewal option on the part of Canada to opt-in at the end of each year through providing written notification for each additional one (1) year period for a total of three (3) years.

9. Estimated value of the proposed contract

The total estimated value of the proposed contract should not exceed \$20,000.00 USD for the first year. If the PMPRB chooses to renew after the first year for an additional year, the estimated value for the second year should not exceed \$20,300.00 USD and \$20,600 USD, respectively for the third year. The total estimated value for the proposed contract for all three years should not exceed \$60,900.00 USD , taxes not applicable.

10. Closing date and time

The closing date and time for accepting Statements of Capabilities is:
September 24, 2019 at 10:00am Eastern Daylight Time (EDT)

11. Contact Person

All inquiries with regard to this Notice must be addressed by e-mail to:

Name: Nadia Laneve

E-Mail: nadia.laneve@pmprb-cepmb.gc.ca